Gilead to price Sovaldi at $900 in India

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD -0.1%) plans to price Sovaldi (sofosbuvir) in India at the same level as Egypt ($900 for the full regimen). In addition, once the clinical trials conclude, the company has agreed to work with Indian generic manufacturers to produce the drug locally and possibly drive the price lower.

Indian officials say that 80% of their population lack insurance so even the bargain price of $900 (compared to the U.S.) will be beyond the means of millions of people.

U.S. patients have the honor of paying $84,000 for the full regimen.